Marathon Trading Investment Management’s Moderna MRNA Stock Holding History

Marathon Trading Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$203K	Sell	4,000 -11,200	-74%	-$523K	0.01%	181
2025 Q4	$448K	Buy	+15,200	New	+$413K	0.01%	190
2025 Q2	–	Sell	-4,800	Closed	-$136K	–	339
2025 Q1	$136K	Buy	+4,800	New	+$170K	0.02%	260
2024 Q4	–	Sell	-1,500	Closed	-$100K	–	349
2024 Q3	$100K	Sell	1,500 -4,500	-75%	-$413K	0.01%	225
2024 Q2	$713K	Buy	6,000 +300	+5%	+$38K	0.05%	121
2024 Q1	$607K	Hold	5,700	–	–	0.05%	142
2023 Q4	$567K	Buy	5,700 +1,500	+36%	+$126K	0.03%	202
2023 Q3	$434K	Buy	4,200 +1,200	+40%	+$134K	0.04%	163
2023 Q2	$365K	Buy	+3,000	New	+$400K	0.03%	142
2023 Q1	–	Sell	-5,500	Closed	-$988K	–	307
2022 Q4	$988K	Buy	5,500 +1,700	+45%	+$278K	0.12%	100
2022 Q3	$449K	Buy	3,800 +2,400	+171%	+$364K	0.04%	161
2022 Q2	$200K	Sell	1,400 -900	-39%	-$129K	0.02%	220
2022 Q1	$396K	Buy	+2,300	New	+$387K	0.03%	191
2020 Q4	–	Sell	-4,800	Closed	-$340K	–	376
2020 Q3	$340K	Buy	+4,800	New	+$335K	0.03%	214

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marathon Trading Investment Management's MRNA Position: Q1 2026 in Review

Marathon Trading Investment Management reduced its Moderna (MRNA) stake by 99% in Q1 2026, selling an estimated $1.59M and leaving 203 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #259.

Marathon Trading Investment Management first reported a position in MRNA in Q4 2020 and has held it in 11 quarters since. The position peaked at $2.84M in Q4 2023. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Marathon Trading Investment Management held 203 shares of Moderna worth $10.3K as of Q1 2026.
Marathon Trading Investment Management sold 34,074 Moderna shares in Q1 2026, an estimated $1.59M.
Moderna made up ﹤0.01% of Marathon Trading Investment Management's portfolio in Q1 2026, its #259 holding.
Marathon Trading Investment Management first reported a position in Moderna in Q4 2020 and has held it in 11 quarters since.
Marathon Trading Investment Management's Moderna position peaked at $2.84M in Q4 2023.
723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Marathon Trading Investment Management's 13F filing for Q1 2026, filed 14 May 2026.